options are potential 5 baggers?, page-10

re: aim listed ... mark the date.
Well, a motherhood statement from PBI this morning ... hopefully to soon be followed by some $-generating announcements. Good to see they are putting last year's revenue figure up front. Not sure people realise that this is no longer just a research and development company. They have the products in the field and they are now ramping up marketing and sales. This is where the growth will come from in the short term.

Company has talked of expotential growth in take up of medicvisions offerings, hope to see same in their shareprice, as ice said earlier its only going to take some nibbles from european instos now they are loisted on aim and with only 50m shares on issue it will be away. slow burn to christmas? possibly, i think the recent interest is such that one or two deals that prove the revenues are growing will provide and immediate boost. I tend to agree with demonic's back of envelope calcs, with good news its not hard to see PBI with a $50million dollar market cap and a shareprice of around .70. Needs a wider re-rating and a strong PR campaign to sell the story.

And this is important ... PBI is not a biotech as such its a device company ... throw in some cutting edge computer software and you have the very field that is generating good returns for small cap companies elsewhere.

----------------------------------------------------
Premier Bionics is focused on the global medical devices and diagnostics markets, estimated
worldwide to be worth approximately US $170 billion in annual expenditure. The Company
currently has two wholly owned subsidiaries: Medic Vision, which is a total solutions provider
offering consultancy implementation and maintenance of virtual reality 3D simulators, which are
designed for use in medical training and Pulmosonix, which is developing technology that enables
non-invasive monitoring of lung inflation needed in the treatment of neonatal infants and adults
suffering respiratory distress.
Commenting today Peter Marks, Executive Chairman of the Company said: “Premier Bionics,
which has already produced revenues of AU$1.63 million for the year ending 31 July 2005, will
continue to develop its existing assets into production and expand sales into new regions such as
China and Europe, while continuing to examine new opportunities to develop near-commercial
technology based medical applications. We believe that an AIM quotation will result in greater
international exposure for the Company and offers the opportunity to gain direct access to the
world’s largest capital markets as we examine potential assets that we can move into near-term
production.”